Molecular Characteristics Predict Clinical Outcomes: Prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene

PURPOSE: To determine if tumor regression following treatment with gefitinib correlates with the presence of sensitizing mutations in EGFR. PATIENTS AND METHODS: Patients with resectable stage I and II non-small cell lung cancer (NSCLC) enriched for the likelihood of EGFR mutation (≤ 15 pack year ci...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Rizvi, Naiyer A., Pao, William, Chaft, Jamie E., Ladanyi, Marc, Miller, Vincent A., Krug, Lee M., Azzoli, Christopher G., Bains, Manjit, Downey, Robert, Flores, Raja, Park, Bernard, Rusch, Valerie, Zakowski, Maureen, Heelan, Robert T., Shen, Ronglai, Kris, Mark G.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2011
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3261615/
https://ncbi.nlm.nih.gov/pubmed/21558399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2102
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares